Eugit Therapeutics
New accelerator entry · 2022-07-01 · the record
In their words
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
What the record says
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Eugit Therapeutics
- Source Check — verify what Eugit Therapeutics states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Eugit Therapeutics for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Eugit TherapeuticsYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Eugit Therapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.